AstraZeneca Discontinues Development of Diabetes Treatment

Drug Industry Daily
KEYWORDS Markets / Rx
A A

AstraZeneca announced May 4 that it is discontinuing development of Galida, a type 2 diabetes treatment, because it could not find evidence that the treatment was appreciably better than current therapy.

To View This Article:

Login

Subscribe To Drug Industry Daily